Therapeutic Antibodies

Woman reaches for inhaler
#Asthma #Bispecific Antibodies #Innovent #Phase I trial

Humanised bispecific antibody for asthma enters Phase I trial

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3002 in healthy participants and… Read More

#News

#Therapeutic Antibodies

App Note: Biologics developability: How Merck creates developability profiles for their mAbs with Prometheus Panta

In this Application Note, discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants.   Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they… Read More

#App Notes

Antibodies
#Antibodies #Flu #Flu vaccine #Immunology / Virology & Vaccines #Influenza #National Institutes of Health (NIH)

Novel antibodies target ‘dark side’ of influenza virus protein

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many… Read More

#Editor's Choice #News

Antibodies
#Antibodies #Oncology #Phase I trial #Solid tumours

Antibody therapy shows anti-tumour activity in advanced cancer

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. CS1002 increases the activation and proliferation of… Read More

#Cancer Research #News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

Peanut butter
#Allergy #FDA #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase III trial

FDA approves first medication to reduce allergic reactions

The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I). The FDA said that Xolair is intended for repeated use to reduce the risk of… Read More

#News #Regulatory

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

New DDW Highlights podcast: 19 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week our news highlights focus on skin conditions, with positive updates on hidradenitis… Read More

#News

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

This week in drug discovery (12-16 February) 

News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer. This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo. The top stories: Dual-action treatment… Read More

#News

Monoclonal antibodies
#Clinical trial #Dermatology #Monoclonal antibodies #Phase III trial #UCB

Monoclonal antibody improves hidradenitis suppurativa by 55%

UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February). Emmanuel… Read More

#News

Scotland
#Biologics #Dermatology #Novartis #Scottish Medicines Consortium (SMC)

New biologic approved in Scotland for hidradenitis suppurativa

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. The advice applies for use in adult patients with… Read More

#News #Regulatory

#Addiction #Antibodies #Cessation Therapeutics #Drug abuse #Monoclonal antibodies #Opioids #Overdose

Can an antibody therapy prevent fentanyl overdoses?

DDW Editor Reece Armstrong speaks to Tracy M Woody, President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. Cessation Therapeutics is a pharmaceutical company that is developing antibody therapies to prevent and reverse overdosing caused by fentanyl. Recently,… Read More

#Exclusive Content

#Bispecific Antibodies #Blood cancer #Cancer research #CAR-T #JAK inhibitor #Oncology

This week in drug discovery (29 January – 2 February) 

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of… Read More

#News

#Antibodies #Antibody discovery workflow #Therapeutic Antibodies #Twist Bioscience

Every day matters

This paid-for advertorial by Twist Bioscience appeared in the Therapeutic Antibodies Guide – DDW Volume 25 – Issue 1, Winter 2023/2024 Improving gene synthesis speed can reduce workflow times, saving you invaluable time, says Twist Bioscience. Time can mean more than money when you’re studying a deadly pathogen. The importance of speed and… Read More

#Exclusive Content

#Bispecific Antibodies #Cancer treatment #Checkpoint inhibitor therapies #Clinical trials #Solid tumours

Phase I trial for first-in-class bispecific antibody for cancer

Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.  The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201.   The study is a European multicentre and… Read More

#Cancer Research #News

View from the International Space Station
#Antibodies #BioOrbit #Manufacturing #Start-ups #Therapeutic Antibodies

Why Carol Vorderman’s daughter is taking antibodies into space

A UK-based start-up is developing technology to build a pharmaceuticals factory in space that will make antibody treatments more accessible and easier to administer. BioOrbit is aiming to build the first pharmaceuticals factory in microgravity and are currently developing a platform for large-scale crystallisation of protein… Read More

#Editor's Choice #News #Start-up Zone

Robot holds up a pill
#AI / data analytics / healthtech / informatics #Cancer research #Cell Science #Immunotherapy #Singapore #SLAS2024 #Therapeutic Antibodies

Read the Winter issue of DDW now

The Winter issue of Drug Discovery World (DDW) is out now and asks whether AI can deliver better immunotherapies for cancer and includes expert predictions on what to expect from the sector in 2024, alongside a supplement looking at SLAS2024 and an exclusive guide exploring therapeutic antibodies. Read More

#News